Drug Profile
TAS 4464
Alternative Names: TAS-4464Latest Information Update: 15 Feb 2021
Price :
$50
*
At a glance
- Originator Taiho Pharmaceutical
- Class Antineoplastics; Small molecules
- Mechanism of Action NEDD 8 activating enzyme inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Endometrial cancer; Haematological malignancies; Multiple myeloma; Non-Hodgkin's lymphoma; Solid tumours
Most Recent Events
- 09 Feb 2021 Taiho Pharmaceutical completes a phase I trial in Haematological malignancies (Late-stage disease, Metastatic disease) in Japan (JapicCTI173488)
- 31 Dec 2019 Discontinued - Phase-I for Haematological malignancies (Late-stage disease, Metastatic disease) in Japan (IV)
- 31 Dec 2019 Discontinued - Phase-I for Haematological malignancies in USA, European Union, Japan (IV)